SARS-CoV-2
ELISA, FCM, IF, Neutralization
Human
IgG1, kappa
CR3009
SARS-CoV-2 (2019-nCoV)
ELISA, Neutralization
Human
IgG1, kappa
Iv0221
SARS-CoV-2 (2019-nCoV)
ELISA, Neutralization
Human
IgG1, kappa
Iv0222
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Neutralization
Human
IgG1, kappa
CC40.8
SARS-CoV-2(2019-nCoV), SARS-CoV
ELISA, Neutralization
Human
IgG1, kappa
S309
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
ELISA, Neutralization
Human
IgG1, kappa
m336
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
ELISA, FCM, Neutralization, SPR
Human
IgG1
7D10
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
FCM, Neutralization, SPR
Human
IgG1
4V2
SARS-CoV-2
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
VIR-7229
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-lambda